---
id: "concept-amc-strategic-financing"
type: "concept"
source_timestamps: ["§ 4. Extend AMC research investments beyond early-stage science."]
tags: ["venture-capital", "funding-models", "commercialization"]
related: ["claim-traditional-funding-insufficient", "entity-cleveland-clinic", "entity-khosla-ventures", "action-strategic-vc-partnerships", "question-mission-fidelity", "contrarian-amcs-as-pharma"]
definition: "The practice of AMCs utilizing venture capital-style funding and partnerships to financially bridge the gap between early-stage basic science and late-stage clinical commercialization."
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# AMC Strategic Financing

To bridge the **"valley of death"** between early-stage discovery and clinical application, AMCs are increasingly acting as **strategic financiers**. Traditional funding sources — **philanthropy, hospital operating margins, and NIH grants** — are insufficient for expensive late-stage clinical development (the core of [[claim-traditional-funding-insufficient]]).

In response, AMCs are **deploying venture-capital-style funding** for internal innovation and **building deep partnerships with traditional venture funds**. The article reports that **over the past decade, U.S. AMCs invested over $24 billion in nearly 700 companies**. The model often uses the health system itself as a **"sandbox"** for portfolio-company incubation, iteration, and implementation — exemplified by [[entity-cleveland-clinic-d2]]'s collaboration with [[entity-khosla-ventures]]. The corresponding move is [[action-strategic-vc-partnerships]] (Pillar 4 of [[framework-amc-innovation-acceleration]]) and it is central to the contrarian argument [[contrarian-amcs-as-pharma]].

**Enrichment caveats:** (1) the **$24B / ~700-company** figure is **not corroborated** by the enrichment sources and should be treated as unverified until backed by primary institutional reporting. (2) VC-style funding is not a universal solution — it can **bias portfolios toward commercially attractive indications** rather than unmet clinical need and expose health systems to financial/reputational risk, feeding directly into [[question-mission-fidelity]].


## Related across articles
- [[prereq-pe-liquidity-events]]